Market Roundup
Dow +13.76 to 16,790.19
S&P -7.13 to 1,979.92
NASDAQ -32.90 to 4,748.36
10-YR Yield -0.02 to 2.04%
Gold +$8.70 to $1,146.40
Oil +$2.39 to $49.14
A series of “bio-bombshells” is hitting the drug stocks where it hurts – in the wallet!

On Sunday, it was the New York Times that published a story headlined: “Valeant’s Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers.”

Yesterday, it was the Wall Street Journal with a story titled “For Prescription Drug Makers, Price Increases Drive Revenue.”

And of course, late last month, the industry got its bogeyman in the form of Martin Shkreli. His company, Turing Pharmaceuticals, bought a drug called Daraprim that treats an infection called toxoplasmosis. Then the company proceeded to hike the price by more than 5,000% before backtracking somewhat.

What the heck is going on?

To read the rest of Mike Larson’s Afternoon Edition, click here ...